MedTrace Logo

Temocillin in ESBL-Enterobacteriaceae Infections

NCT05413772 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2023-02-06

No results posted yet for this study

Summary

Because of the increasing incidence of infections with multi-drug resistant enterobacteriaceae, we need alternative treatments to spare carbapenems. Temocillin could be an interesting option but its position is only defined for the curative treatment of urinary tract infections. We would like to explore others indications comparing two groups : one using temocillin empirically for treatment or prophylaxis and the second using it in second line whatever the indication is.

Conditions

Interventions

OTHER

Temocillin

To evaluate the clinical course of patients who received temocillin. To evaluate the efficacy and safety of temocillin in different situations Enterobacteriaceae ESBL infections

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Isabelle Bonnet, MD · Pitie-Salpetriere University Hospital

  • Sophie Vimont, MD · Tenon Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-20
Primary Completion
2022-11-24
Completion
2022-11-24

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05413772 on ClinicalTrials.gov